Safety and Efficacy Study of an A1-Adenosine Receptor Agonist to Slow Heart Rate in Atrial Fibrillation
Information source: Aderis Pharmaceuticals
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Atrial Fibrillation
Intervention: DTI-0009 (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: Aderis Pharmaceuticals
Summary
This study is designed to evaluate the safety of DTI-0009 in patients with atrial
fibrillation and to find the dose of DTI-0009 that lowers heart rates in patients with atrial
fibrillation with rapid ventricular response.
Clinical Details
Study design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment
Eligibility
Minimum age: 18 Years.
Maximum age: 85 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria
- Primary diagnosis of atrial fibrillation with rapid ventricular response of any
duration as documented by an ECG
Exclusion Criteria
- Presence of other significant cardiac disease or history of significant neurological,
hepatic,cardiovascular, renal, gastrointestinal, thyroid, respiratory, rheumatologic,
or hematologic disease or impairment that in the investigator’s judgment is serious
enough to preclude the patient from safely participating in the study
Locations and Contacts
Multiple locations, Richmond, Virginia, United States
Additional Information
Last updated: June 23, 2005
|
